Azitra, Inc.

AZTR Healthcare Biotechnology

Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023. In the quarter to June 2026, EPS grew 85.6% and free cash flow fell 19.6%, each against the same quarter a year earlier.

0.07 0.00 0.00%
Market cap
$4.3M
P/E
1.0×
Fwd P/E
−0.1×
Dividend yield
—
F-score
3/9
Altman Z
−14.66
Beneish M
13.02
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

— — — —
EV/Sales
— — — —
EV/FCF
— — — —
Current Ratio
1.23 2.83 6.94 4.86
Net Debt/EBITDA
0.53 0.98 3.15 2.04
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow Yield
— — — —
Free Cash Flow per Share
(0.60) (0.61) (0.16) (0.18)
Book value per Share
0.55 0.78 0.68 0.38
Free Cash Flow
(2.49) (2.98) (2.51) (3.41)
EV/EBIT
— — — —
Other line items

Show all line items

Columns are period end dates